literature1

To Evaluate the Association between Gln223Arg,Lys109Arg Polymorphisms in Leptin Receptor Gene and Essential Hypertension: an Update Meta-analysis

Abstract | PDF | HTML | Order a Reprint

January 01, 2018.   doi:10.12123/npcd201801002

BIOWED January 01, 2018 To read the full article

Metrics: PDF views | HTML views



Liu Liu, Lingli Zhang*

School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.

Communication: willow_liu@126.com (Liu Liu)

Keywords: Hypertension; Leptin receptor; Gene polymorphisms; Risk; Meta-analysis

Received: September 01,2017 Accept: November 01,2017 published:January 01,2018

ABSTRACT

Studies have shown that the single nucleotide polymorphisms of the leptin receptor gene may increase the risk of essential hypertension. However, there still no consistent conclusion has been drawn. In this study, the meta-analysis was used to summarized the association in LEPR Gln223Arg, Lys109Arg polymorphisms and the risk of essential hypertension based on 16 case–control studies retrieved from Pubmed, Web of Science, CNKI, VIP, CBM. Statistical analyses were carried out with the Stata12.0 and Revman5.3 software. In the 13 articles that covered the Gln223Arg polymorphism, a significant association was found between Gln223Arg gene polymorphism and essential hypertension in allelic model (OR=1.36; 95% CI:1.10-1.69), dominant genetic model (OR=1.48; 95% CI:1.14-1.93) and recessive genetic model (OR=1.27; 95%CI: 1.04-1.55). In the 10 articles which were related to Lys109Arg polymorphism, no significant association was found between the Lys109Arg polymorphism and essential hypertension risk under allelic model (OR= 1.02; 95% CI: 0.86-1.21), dominant genetic model (OR=1.00; 95% CI:0.81-1.23) and recessive genetic model (OR=1.11; 95% CI:0.86-1.44). In summary, the variation of Gln223Arg locus can increase the risk of essential hypertension significantly, but there is no evidence shows association between Lys109Arg polymorphism and essential hypertension.

Copyright © 2017-2018 Biowed Scientific Publisher,2016-2018 Guangzhou aojin technology co., LTD. All rights reserved  Yue ICP 18036074